Navigation Links
Gene in eye melanomas linked to good prognosis
Date:1/16/2013

rom 102 patients, finding it in nearly 20 percent of them. Mutations in the gene were linked to favorable features, including a younger age at diagnosis and a far lower metastasis rate.

Interestingly, SF3B1 mutations always occurred at the same site of the gene. And the SF3B1 and BAP1 mutations were found to be almost mutually exclusive, meaning that if patients had a mutation in one of the genes, they were unlikely to have a mutation in the other.

"This suggests mutations in these genes may represent alternative pathways in tumor progression," Bowcock says.

The SF3B1 gene also has been reported recently by other researchers to be mutated in a pre-leukemia illness called myelodysplastic syndrome. For these patients, SF3B1 mutations mean the condition is less likely to develop into a full-blown leukemia. Changes in the SF3B1 gene also have been found in chronic lymphocytic leukemia and less frequently in breast cancer and other solid tumors. The gene's link to prognosis is unclear for these cancers.

Normally, the SF3B1 gene is involved in converting DNA's chemical cousin, RNA, into messenger RNA. This messenger molecule carries DNA's code and serves as a template for making proteins. The researchers don't yet understand how mutations in this gene are involved in cancer but it's the next step of their research.

"We want to understand the functional consequences of mutations in SF3B1," Bowcock says. "How are changes in this gene linked to cancer development? This is the fourth gene known to be mutated in uveal melanoma along with BAP1 and the genes GNAQ and GNA11. A complete understanding of the molecular basis of this tumor will be invaluable in predicting prognosis and in the identification and development of novel treatments for this cancer."


'/>"/>

Contact: Caroline Arbanas
arbanasc@wustl.edu
314-286-0109
Washington University School of Medicine
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Exposure to antibiotics linked to severity of allergic asthma: UBC research
2. Autism risk gene linked to differences in brain structure
3. Spontaneous gene glitches linked to autism risk with older dads
4. Dental X-rays linked to common brain tumor
5. Ocean acidification linked to larval oyster failure
6. First mass extinction linked to marine anoxia
7. Prenatal exposure to air pollution linked to childhood obesity
8. Knee injuries in women linked to motion, nervous system differences
9. Researchers discover first gene linked to missing spleen in newborns
10. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
11. University of Leicester study finds low agreeableness linked to a preference for aggressive dogs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene in eye melanomas linked to good prognosis
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
(Date:5/28/2015)... 28, 2015 Industry analyst firm n-tech ... report titled "Markets for Self-Healing Materials: 2015-2022." According to ... and vascular systems, biomaterials, relevant shape memory materials ... $2.7 billion by 2020. The report ... of smart materials. Other recent n-tech reports have included ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... For coffee lovers, the first cup of the morning is one ... grounds could eliminate one of the worst smells around sewer ... remove toxic gases from the air, scientists at The City College ... coffee grounds can sop up hydrogen sulfide gas, the chemical that ...
... DURHAM, N.H. Americans, knowledge of facts about the ... but this increase in knowledge has not translated into ... research from the Carsey Institute at the University of ... issues improved from 2006 to 2010, consistent with hopes ...
... Second Class? Confronting the Risks to U.S. ... Research Foruma unique interactive gathering of top policy ... agencies for health research, as well as nationally ... Two panels will each be followed by Q&A, ...
Cached Biology News:Carbonized coffee grounds remove foul smells 2Carsey Institute: Americans' knowledge of polar regions up, but not their concern 2World class to second class? Confronting the risks to US science and innovation 2
(Date:5/30/2015)... The Cholangiocarcinoma Foundation (CCF), a ... duct cancer, announced today the first grant recipients ... , The Foundation has awarded 5 grants ... to raise awareness about cholangiocarcinoma and inspire innovative, ... opens new pathways for diagnosis and drug discovery ...
(Date:5/30/2015)... , May 30, 2015 CTI BioPharma ... International,s Bioscience business (NYSE: BAX ) today announced ... trial examining pacritinib for the treatment of myelofibrosis – ... Annual Meeting of the American Society of Clinical Oncology ... Ill. Pacritinib is an investigational oral multikinase ...
(Date:5/30/2015)... RARITAN, N.J. , May 30, 2015 /PRNewswire/ ... Phase 2 MMY2002 (SIRIUS) trial show treatment with ... antibody – achieved an overall response rate (ORR) ... by an independent review committee, in heavily pre-treated ... among the pre-specified subgroups based on age, prior ...
(Date:5/30/2015)... IRVING, Texas , May 30, 2015 /PRNewswire/ ... data from a study in which researchers identified ... of metachronous paired glioma tumors, indicating changes in ... study observing 19 patients was a subset of ... confirmed molecular heterogeneity of the cancer. These data ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... , CRANBURY, N.J., Aug. 12 Palatin Technologies, Inc. ... raise approximately $3.1 million in gross proceeds, before deducting placement agent ... of 9.5 million units, at a price of $0.33 per unit. ... and (ii) a warrant exercisable at any time on or after ...
... , OMAHA, Neb., Aug. 12 Transgenomic Inc. (OTC Bulletin Board: TBIO) announces ... Transgenomic Inc. Second Quarter 2009 Earnings Release, ... 2009 @ 5:00 p.m. Eastern, Where: http://www.transgenomic.com/events.asp?id=6 , ... at the, address above., ...
... , , WALTHAM, Mass., ... research and advisory firms focusing on pharmaceutical and healthcare issues, ... share in second- and third-line therapy since last year,s analysis ... attributed to the publication of the ENHANCE trial which called ...
Cached Biology Technology:Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering 2Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering 3Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 2Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 3